Literature DB >> 33556543

Increased transcription and high translation efficiency lead to accumulation of androgen receptor splice variant after androgen deprivation therapy.

Tianfang Ma1, Shanshan Bai1, Yanfeng Qi1, Yang Zhan1, Nathan Ungerleider2, Derek Y Zhang3, Taavi Neklesa4, Eva Corey5, Scott M Dehm6, Kun Zhang7, Erik K Flemington8, Yan Dong9.   

Abstract

Upregulation of androgen receptor splice variants (AR-Vs), especially AR-V7, is associated with castration resistance of prostate cancer. At the RNA level, AR-V7 upregulation is generally coupled with increased full-length AR (AR-FL); consequently, AR-V7 and AR-Vs collectively constitute a minority of the AR population. However, Western blotting showed that the relative abundance of AR-V proteins is much higher in many castration-resistant prostate cancers (CRPCs). To address the mechanism underlying this discrepancy, we analyzed RNA-seq data from ~350 CRPC samples and found a positive correlation between all canonical and alternative AR splicing. This indicates that increased alternative splicing is not at the expense of canonical splicing. Instead, androgen deprivation releases AR-FL from repressing the transcription of the AR gene to induce coordinated increase of AR-FL and AR-V mRNAs. At the protein level, however, androgen deprivation induces AR-FL, but not AR-V, degradation. Moreover, AR-V7 is translated much faster than AR-FL. Thus, androgen-deprivation-induced AR-gene transcription and AR-FL protein decay, together with efficient AR-V7 translation, explain the discrepancy between the relative AR-V mRNA and protein abundances in many CRPCs, highlighting the inevitability of AR-V induction after endocrine therapy.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AR negative autoregulation; AR-V mRNA stability; AR-V protein stability; AR-V translation; Castration resistance; Castration-resistant prostate cancer

Mesh:

Substances:

Year:  2021        PMID: 33556543      PMCID: PMC7940584          DOI: 10.1016/j.canlet.2020.12.037

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  47 in total

1.  Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.

Authors:  Shihua Sun; Cynthia C T Sprenger; Robert L Vessella; Kathleen Haugk; Kathryn Soriano; Elahe A Mostaghel; Stephanie T Page; Ilsa M Coleman; Holly M Nguyen; Huiying Sun; Peter S Nelson; Stephen R Plymate
Journal:  J Clin Invest       Date:  2010-07-19       Impact factor: 14.808

2.  AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.

Authors:  Tilman Todenhöfer; Arun Azad; Craig Stewart; Jian Gao; Bernhard J Eigl; Martin E Gleave; Anthony M Joshua; Peter C Black; Kim N Chi
Journal:  J Urol       Date:  2016-07-17       Impact factor: 7.450

Review 3.  Emerging data on androgen receptor splice variants in prostate cancer.

Authors:  Subing Cao; Yang Zhan; Yan Dong
Journal:  Endocr Relat Cancer       Date:  2016-10-04       Impact factor: 5.678

4.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

Authors:  Emmanuel S Antonarakis; Changxue Lu; Hao Wang; Brandon Luber; Mary Nakazawa; Jeffrey C Roeser; Yan Chen; Tabrez A Mohammad; Yidong Chen; Helen L Fedor; Tamara L Lotan; Qizhi Zheng; Angelo M De Marzo; John T Isaacs; William B Isaacs; Rosa Nadal; Channing J Paller; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Jun Luo
Journal:  N Engl J Med       Date:  2014-09-03       Impact factor: 91.245

5.  Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.

Authors:  Manish Kohli; Yeung Ho; David W Hillman; Jamie L Van Etten; Christine Henzler; Rendong Yang; Jamie M Sperger; Yingming Li; Elizabeth Tseng; Ting Hon; Tyson Clark; Winston Tan; Rachel E Carlson; Liguo Wang; Hugues Sicotte; Ho Thai; Rafael Jimenez; Haojie Huang; Peter T Vedell; Bruce W Eckloff; Jorge F Quevedo; Henry C Pitot; Brian A Costello; Jin Jen; Eric D Wieben; Kevin A T Silverstein; Joshua M Lang; Liewei Wang; Scott M Dehm
Journal:  Clin Cancer Res       Date:  2017-05-04       Impact factor: 12.531

6.  SF3B2-Mediated RNA Splicing Drives Human Prostate Cancer Progression.

Authors:  Norihiko Kawamura; Keisuke Nimura; Kotaro Saga; Airi Ishibashi; Koji Kitamura; Hiromichi Nagano; Yusuke Yoshikawa; Kyoso Ishida; Norio Nonomura; Mitsuhiro Arisawa; Jun Luo; Yasufumi Kaneda
Journal:  Cancer Res       Date:  2019-08-20       Impact factor: 12.701

7.  Interplay between Cytoplasmic and Nuclear Androgen Receptor Splice Variants Mediates Castration Resistance.

Authors:  Yang Zhan; Guanyi Zhang; Xiaojie Wang; Yanfeng Qi; Shanshan Bai; Dongying Li; Tianfang Ma; Oliver Sartor; Erik K Flemington; Haitao Zhang; Peng Lee; Yan Dong
Journal:  Mol Cancer Res       Date:  2016-09-26       Impact factor: 5.852

8.  Integrative clinical genomics of advanced prostate cancer.

Authors:  Dan Robinson; Eliezer M Van Allen; Yi-Mi Wu; Nikolaus Schultz; Robert J Lonigro; Juan-Miguel Mosquera; Bruce Montgomery; Mary-Ellen Taplin; Colin C Pritchard; Gerhardt Attard; Himisha Beltran; Wassim Abida; Robert K Bradley; Jake Vinson; Xuhong Cao; Pankaj Vats; Lakshmi P Kunju; Maha Hussain; Felix Y Feng; Scott A Tomlins; Kathleen A Cooney; David C Smith; Christine Brennan; Javed Siddiqui; Rohit Mehra; Yu Chen; Dana E Rathkopf; Michael J Morris; Stephen B Solomon; Jeremy C Durack; Victor E Reuter; Anuradha Gopalan; Jianjiong Gao; Massimo Loda; Rosina T Lis; Michaela Bowden; Stephen P Balk; Glenn Gaviola; Carrie Sougnez; Manaswi Gupta; Evan Y Yu; Elahe A Mostaghel; Heather H Cheng; Hyojeong Mulcahy; Lawrence D True; Stephen R Plymate; Heidi Dvinge; Roberta Ferraldeschi; Penny Flohr; Susana Miranda; Zafeiris Zafeiriou; Nina Tunariu; Joaquin Mateo; Raquel Perez-Lopez; Francesca Demichelis; Brian D Robinson; Marc Schiffman; David M Nanus; Scott T Tagawa; Alexandros Sigaras; Kenneth W Eng; Olivier Elemento; Andrea Sboner; Elisabeth I Heath; Howard I Scher; Kenneth J Pienta; Philip Kantoff; Johann S de Bono; Mark A Rubin; Peter S Nelson; Levi A Garraway; Charles L Sawyers; Arul M Chinnaiyan
Journal:  Cell       Date:  2015-05-21       Impact factor: 41.582

9.  Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer.

Authors:  J Edwards; N S Krishna; K M Grigor; J M S Bartlett
Journal:  Br J Cancer       Date:  2003-08-04       Impact factor: 7.640

10.  Regulation of androgen receptor splice variant AR3 by PCGEM1.

Authors:  Ziqiang Zhang; Nanjiang Zhou; Jianguo Huang; Tsui-Ting Ho; Zhuxian Zhu; Zhongmin Qiu; Xinchun Zhou; Chunxue Bai; Fangting Wu; Min Xu; Yin-Yuan Mo
Journal:  Oncotarget       Date:  2016-03-29
View more
  7 in total

1.  AR Structural Variants and Prostate Cancer.

Authors:  Laura Cato; Maysoun Shomali
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

Review 2.  From Omics to Multi-Omics Approaches for In-Depth Analysis of the Molecular Mechanisms of Prostate Cancer.

Authors:  Ekaterina Nevedomskaya; Bernard Haendler
Journal:  Int J Mol Sci       Date:  2022-06-03       Impact factor: 6.208

3.  Cistrome and transcriptome analysis identifies unique androgen receptor (AR) and AR-V7 splice variant chromatin binding and transcriptional activities.

Authors:  Paul Basil; Matthew J Robertson; William E Bingman; Amit K Dash; William C Krause; Ayesha A Shafi; Badrajee Piyarathna; Cristian Coarfa; Nancy L Weigel
Journal:  Sci Rep       Date:  2022-03-30       Impact factor: 4.379

4.  The kinesin KIF20A promotes progression to castration-resistant prostate cancer through autocrine activation of the androgen receptor.

Authors:  Valeria A Copello; Kerry L Burnstein
Journal:  Oncogene       Date:  2022-04-13       Impact factor: 8.756

Review 5.  Androgen receptor signaling and spatial chromatin organization in castration-resistant prostate cancer.

Authors:  Tianyi Zhou; Qin Feng
Journal:  Front Med (Lausanne)       Date:  2022-07-29

Review 6.  A narrative review of the role of glucocorticoid receptors in prostate cancer: developments in last 5 years.

Authors:  Feng Zhou; Yue Shi; Guan'an Zhao; Stefan Aufderklamm; Katie S Murray; Baiye Jin
Journal:  Transl Androl Urol       Date:  2022-08

7.  Androgen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells.

Authors:  Jiaqian Liang; Liyang Wang; Larysa Poluben; Mannan Nouri; Seiji Arai; Lisha Xie; Olga S Voznesensky; Laura Cato; Xin Yuan; Joshua W Russo; Henry W Long; Myles Brown; Shaoyong Chen; Steven P Balk
Journal:  Cancer Lett       Date:  2021-07-10       Impact factor: 8.679

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.